When falsified medicines enter the supply chain: Description of an incident in Kenya and lessons learned for rapid response

Journal of Public Health Policy

Volumn 34, Issue 1, 2013, Pages 22-30

  Cohn, Jennifer ^a   Von Schoen Angerer, Tido ^b   Jambert, Elodie ^b   Arreghini, Guido ^b   Childs, Michelle ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b MÉDECINS SANS FRONTIÈRES   (Switzerland)

Author keywords

antiretroviral therapy; falsified medicine; Kenya; pharmacovigilance

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; COUNTERFEIT DRUG;

FRAUD; HUMAN; KENYA; LEGISLATION AND JURISPRUDENCE; PATIENT SAFETY; STANDARDS; SUPPLY AND DISTRIBUTION;

ANTI-HIV AGENTS; COUNTERFEIT DRUGS; FRAUD; HUMANS; KENYA; PATIENT SAFETY;

EID: 84873943546     PISSN: 01975897     EISSN: 1745655X     Source Type: Journal    
DOI: 10.1057/jphp.2012.53     Document Type: Article

References (13)

1. World Health Organization. (2010) Medicines: spurious/falsely-labelled/ falsified/counterfeit (SFFC) medicines. Fact sheet N1275. (January) World Health Organization, Geneva, http://www.who.int/mediacentre/factsheets/fs275/en/index. html, accessed 23 March 2012.
2. Caudron, J.M., Ford, N., Henkens, M., Mace, C., Kiddell-Monroe, R. and Pinel, J. (2008) Substandard medicines in resource-poor settings: A problem that can no longer be ignored. Tropical Medicine and International Health 13(8): 1062-1072.
3. WHO. (2011) Report of the Working Group of Member States on Substandard/Spurious/Falsely-labeled/Falsified/Counterfeit Medical Products. 24 March, http://apps.who.int/gb/ebwha/pdf-files/WHA64/A64-16-en.pdf, accessed 30 July 2012.
4. Time to focus on quality. (February 2011) MSF Briefing Note ahead of the February 2011 meeting of the Working Group of WHO Member States on Substandard/spurious/falsely-labelled/falsified/counterfeit medical products. Médecins Sans Frontières, http://www.msfac-cess.org/content/ briefing-note-time-focus-quality, accessed 24 September 2012.
5. Park, C.S. (2009) Legal Aspects of Defining 'Counterfeit Medicines': A Discussion Paper. New Delhi: World Health Organization, Regional Office for South East Asia.
6. WHO. (2012) Prequalification of Medicines by the WHO. Factsheet, http://www.who.int/mediacentre/factsheets/fs278/en/index.html, accessed 30 July 2012.
7. Prequalification of Medicines Programme. (2011) Additional information regarding falsified lamivudine, zidovudine and nevirapine tablets (Zidolam-N) in Kenya (6 October 2011) WHO Prequalification of Medicines Programme, http://apps.who.int/prequal/info-press/documents/Falsified-ZidolamN- 06October2011.pdf, accessed 23 March 2012.
8. MSF Access Campaign. (2011) Falsified lamivudine, zidovudine and nevirapine tablets(Zido-lam-N) in Kenya (23 September 2011), http://apps.who.int/prequal/info-press/documents/Falsified-ZidolamN- 23September2011.pdf, accessed 23 March 2012.
9. Falsified Medicines Enter Supply Chain in Kenya. (30 September 2011) Médecins Sans Frontières Press Release, http://www.msfaccess.org/ resources/press-releases/1644, accessed 23 March 2012.
10. Kenya National Council for Law Reporting. (2010) The Industrial Property Act, http://www.kenyalaw.org/klr/fileadmin/pdfdownloads/Acts/ IndustrialPropertyActCap509.pdf, accessed 30 July 2012.
11. WHO. (1999) Guidelines for the development of measures to combat counterfeit drugs. January, http://whqlibdoc.who.int/hq/1999/WHO-EDM-QSM-99.1. pdf, accessed 30 July 2012.
12. Republic of Kenya High Court. (2009) Republic of Kenya in the High Court of Kenya at Nairobi Petition No. 409 of 2009, http://kelinkenya.org/wp-content/ uploads/2012/04/Judgment-Petition-No-409-of-20092.pdf, accessed 30 July 2012.
13. Musungu, S. (2010) The Potential Impact of the Proposed East African Community (EAC) Anti-Counterfeiting Policy and Bill on Access to Essential Medicines. UNDP Commissioned Discussion Paper.